💊
Lynozyfic
linvoseltamab
Mielom multiplu
✅ Autorizat
✅
Nu există alerte active
Acest medicament nu are penurii în curs, scrisori de siguranță sau retrageri de pe piață.
La ce se utilizează
Monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
⚠️ Siguranță a pacientului
No
Pagina oficială EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/lynozyfic